青光眼术后抗滤过泡瘢痕化药物进展

青光眼是全世界排名第二位的导致视力下降或丧失的眼病,对视力的损害严重且不可逆,使青光眼的早期诊断和治疗显得尤为重要。目前,青光眼滤过性手术仍是降低患者眼内压最有效的治疗方法,但经滤过减压术后,青光眼患者滤过泡成纤维细胞的增殖和胶原的沉积,会导致滤过泡功能不同程度的减退,减少了滤过性手术的成功率。为减轻这种不必要的瘢痕愈合,一些抗瘢痕形成药物被越来越多应用于青光眼滤过手术的实验与临床研究中。本文对目前这些主要的青光眼滤过性手术后抗滤过泡瘢痕的药物的作用机制及临床治疗效果进行综述。

Progress of The Anti-scarring Drugs in Bleb after Trabeculectomy

Glaucoma is the second eye diseases in the world that leads to vision loss or loss of serious irreversible damage to vision. It is particularly important to make early diagnosis and treatment of glaucoma. Currently, glaucoma filtration surgery which reduces the patient''s intraocular pressure(IOP) is the most effective treatment method. But excessive fibroblastic proliferation, an increase in collagen deposition and the formation of scar result in the bleb dysfunction after trabeculectomy, which leads to decrease success rate of filtration surgery. To alleviate this unnecessary scar healing, anti-scarring drugs are more and more frequently used in glaucoma filtration surgeryinexperimental andclinical studies. Therefore, thisreviewfocusesonthemainlyanti-scarringdrugs after glaucoma filtrationsurgery.